Worth reading
46Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-7.8
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2022年4月1日〜2022年12月31日ConsolidatedIFRSNet Sales109,919¥ millionYear on year +3.4%Progress 78.0%
Operating profit27,987¥ millionYear on year -7.8%Progress 93.3%
Ordinary income28,422¥ millionYear on year -7.5%Progress 93.5%
Net income attributable to owners of the parent22,674¥ millionYear on year -1.7%Progress 94.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share336.65円
Financial position at period-end
Total assets231,876¥ million
of which net assets 195,968 ¥ millionEquity ratio 84.4%vs. prior year-end +2.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+12,618
Investment-9,421
Financials-8,922
Net change-5,725
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥54,919 million
Segment revenuePharmaceuticals Business ¥93,095 million (YoY -0.6%), Functional Foods Business ¥16,824 million (YoY +32.8%)
Segment profitPharmaceuticals Business ¥27,297 million, Functional Foods Business ¥491 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥141,000 million (YoY +2.6%)
Operating profit¥30,000 million (YoY -8.9%)
Ordinary income¥30,400 million (YoY -8.7%)
Net income¥24,000 million (YoY -3.9%)
Revision to Earnings ForecastNet Sales No revision / Operating profit No revision / Ordinary income No revision / Net income No revision
Annual Dividend Forecast¥110.00 → ¥114.00（+3.6%）
Factors Behind Changes in Business Performance
前年同期にあった優先審査バウチャーの売却一時金収入の反動、売上構成による売上原価率の上昇、薬価改定など。機能食品事業ではプロテイン製剤等の売上が増加した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Name of newly added company Not disclosed / Excluded Company Name Not disclosed
Depreciation and amortization¥3,679 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Conference call for institutional investors and securities analysts
Issued Shares at Period-End70,251,484 Shares
Treasury Shares at Period-End2,898,549 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2022年4月1日〜2022年12月31日 |
| Net Sales | ¥109,919 million (YoY +3.4%) |
| Operating profit | ¥27,987 million (YoY -7.8%) |
| Ordinary income | ¥28,422 million (YoY -7.5%) |
| Profit attributable to owners of the parent | ¥22,674 million (YoY -1.7%) |
| Net income per share | 336.65円 |
| Equity ratio | End of the current fiscal period 84.4 / End of previous period 82.1 |
| Total assets | ¥231,876 million |
| Net assets | ¥195,968 million |
| Cash flows from operating activities | ¥12,618 million |
| Cash flows from investing activities | ¥-9,421 million |
| Cash flows from financing activities | ¥-8,922 million |
| Cash and cash equivalents at end of period | ¥54,919 million |
| Full-year earnings forecast | Net Sales ¥141,000 million (YoY +2.6%) / Operating profit ¥30,000 million (YoY -8.9%) / Ordinary income ¥30,400 million (YoY -8.7%) / Net income ¥24,000 million (YoY -3.9%) |
| Revision to Earnings Forecast | Net Sales No revision / Operating profit No revision / Ordinary income No revision / Net income No revision |
| Annual Dividend Forecast | ¥110.00 → ¥114.00（+3.6%） |
| Segment revenue | Pharmaceuticals Business ¥93,095 million (YoY -0.6%), Functional Foods Business ¥16,824 million (YoY +32.8%) |
| Segment profit | Pharmaceuticals Business ¥27,297 million, Functional Foods Business ¥491 million |
| Depreciation and amortization | ¥3,679 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Name of newly added company Not disclosed / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Conference call for institutional investors and securities analysts |
| Issued Shares at Period-End | 70,251,484 Shares |
| Treasury Shares at Period-End | 2,898,549 Shares |
| Factors Behind Changes in Business Performance | 前年同期にあった優先審査バウチャーの売却一時金収入の反動、売上構成による売上原価率の上昇、薬価改定など。機能食品事業ではプロテイン製剤等の売上が増加した。 |
Items this document does not state (8)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.前年同期にあった優先審査バウチャーの売却一時金収入の反動、売上構成による売上原価率の上昇など。医薬品事業では薬価改定も減収要因となり、機能食品事業ではプロテイン製剤等の売上増加が増収要因となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.